• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Ven­ter quick­ly grabs the reins back at Hu­man Longevi­ty; Pe­ter Thiel backs up­start ChemomAb

8 years ago
News Briefing

Stealthy Sil­ver­back re­cruits Seat­tle Ge­net­ics’ Er­ic Dob­meier as CEO, fill­ing C-suite with on­col­o­gy tal­ent

8 years ago
People

CRISPR/Cas9 pi­o­neer Chad Cow­an en­lists in Mus­tang Bio’s CAR-T quest

8 years ago
People

Atox Bio clos­es $30M round as it speeds through late-stage tri­als

8 years ago
Financing

Ul­tragenyx shares surge as block­buster hope­ful buro­sum­ab con­tin­ues to per­form in piv­otal study

8 years ago
R&D

J&J adds PhI­II hy­per­ten­sion drug to the pipeline with $230M-plus cash deal for Idor­sia

8 years ago
Pharma

Sanofi’s be­lat­ed ad­mis­sion of a lethal Deng­vax­ia threat came long af­ter mul­ti­ple high-pro­file warn­ings

8 years ago
R&D

Sanofi’s bad, aw­ful, ter­ri­ble de­vel­op­ment week ends with PhI­II C. diff fail­ure

8 years ago
R&D

Lau­ra Shawver hits the ground run­ning, scout­ing new in­vestors for tiny Syn­thorx

8 years ago
Peer Review

Te­va boots its R&D chief; Iron­wood grows the C-suite and In­ter­cept taps new EVP of re­search

8 years ago
Peer Review

Ac­tive Biotech shares crater af­ter Teva's MS drug laquin­i­mod flops (again); FDA ap­proves Foun­da­tion Med­i­cine's ...

8 years ago
News Briefing

Re­searchers use PD-1 check­point drug in pur­suit of a promis­ing cu­ra­tive ap­proach to HIV

8 years ago
R&D

Bris­tol-My­ers set to get a boost in Chi­na as Op­di­vo aces PhI­II lung can­cer study ear­ly

8 years ago
R&D

Astel­las forges a $390M deal to buy a biotech fo­cused on Ronald Evans’ ‘ex­er­cise-in-a-pill’ tech

8 years ago
Pharma

Shire CEO Orn­skov woos Bay­er’s An­dreas Busch to run Boston-based R&D group

8 years ago
People
R&D

What's killing pa­tients in Bay­er's Xofi­go com­bo study? Re­searchers un­blind study ear­ly to probe safe­ty alert

8 years ago
R&D
Pharma

In­di­v­ior tight­ens grip on opi­oid ad­dic­tion mar­ket with Sublo­cade's new FDA ap­proval

8 years ago
Pharma

Cures Act im­ple­men­ta­tion: Got­tlieb says faster can­cer drug ap­provals com­ing for sec­ondary in­di­ca­tions

8 years ago
Pharma

Sen­a­tors grill Alex Azar on drug prices; Mor­phoSys sells rights to Darza­lex ri­val in $120M deal; Se­r­i­al deal­mak­er ...

8 years ago
News Briefing

In re­or­ga­ni­za­tion, Jo­erg Moeller gath­ers all the phar­ma R&D reins at Bay­er as dis­cov­ery chief ex­its

8 years ago
People
R&D

An­ti-ag­ing start­up ResTOR­bio gets $40M to fu­el Phase IIb study

8 years ago
Financing

Ma­jor dereg­u­la­tion? FDA with­draws sev­er­al rules and reg­u­la­tions re­lat­ed to med­ical prod­ucts

8 years ago
Pharma

Af­ter all the love and mon­ey, an­a­lysts spec­u­late that J&J may swoop in with a buy­out of­fer for Gen­mab

8 years ago
Deals
Pharma

Sanofi’s dengue vac­cine slams in­to a safe­ty is­sue, trig­ger­ing a $120M write-off and evis­cer­at­ing old block­buster ...

8 years ago
R&D
First page Previous page 1065106610671068106910701071 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.